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miR-150 regulates obesity-
associated insulin resistance by 
controlling B cell functions
Wei Ying1,*, Alexander Tseng2,*, Richard Cheng-An Chang3, Haiqing Wang3, Yu-lieh Lin3, 
Srikanth Kanameni3, Tyler Brehm4, Andrew Morin3, Benjamin Jones5, Taylor Splawn6, 
Michael Criscitiello7, Michael C. Golding2, Fuller W. Bazer1, Stephen Safe3 & Beiyan Zhou8
Adipose tissue resident B cells account for more than 20% of stromal cells within visceral adipose 
tissues; however, their functions in the adipose tissue niche are poorly elucidated. Here we report that 
miR-150 modulates adipose tissue function by controlling activation of B cells and their interactions 
with other immune cells. miR-150KO mice displayed exacerbated obesity-associated tissue 
inflammation and systemic insulin resistance, which is recapitulated by adoptive transfer of B cells, 
but not purified immunoglobulin, into obese Bnull mice. Using purified cell populations, we found that 
enhanced proinflammatory activation of adipose tissue T cells and macrophages was due to miR-150KO 
B cells action but not cell-autologous mechanisms. miR-150KO B cells displayed significantly enhanced 
antigen presentation upon stimulation, ultimately leading to elevated inflammation and insulin 
resistance, compared to wild type B cells. Knockdown of identified miR-150 target genes, Elk1, Etf1 or 
Myb attenuated B cell action by altering B cell receptor pathways and MHCII cell surface presentation. 
Our results demonstrate a critical role for miR-150 in regulating B cell functions in adipose tissue which 
ultimately regulate both metabolic and immunologic homeostasis in the adipose tissue niche.
Metainflammation and insulin resistance are two hallmarks of obesity which contribute to the pathogenesis of 
obesity-associated diseases, including type 2 diabetes and cardiovascular diseases1–4. Expansion of visceral adi-
pose tissue (VAT) is central to the development of obesity associated metabolic syndromes, characterized by 
adipocyte malfunction and altered tissue specific immune cell profiles1,3. Adipose tissue immune cells vary in 
number and their responses to obese stress5. To control the detrimental effects of obesity, it is important to under-
stand the regulatory networks controlling adipose tissue immune cell activation and their interactions within the 
tissue niche.
The complex immune profile within visceral adipose stroma (VSC) consists of various dynamically interacting 
cell types which are central to adipose tissue metabolic and immunologic homeostasis. Among VSC immune 
cells, adipose tissue macrophages (ATMs) account for 30–40% of VSC and the regulation of their activation has 
been extensively studied6,7. ATMs display a wide-range of activation statuses from alternative activation (M2) 
in lean tissue to the predominantly classical pro-inflammatory state (M1) in obese tissues6–8. Previous research, 
including our own, has revealed several key regulators controlling ATM polarization, including nuclear factor 
κ B/c-Jun N-terminal kinase (NFκ B/JNK), peroxisome proliferator-activated receptor γ (PPARγ ), and microR-
NAs9–13. In addition, adipose tissue T cells (ATTs) comprise approximately 10% of obese VSCs and fine-tune 
the adipose tissue immune environment through direct cell-cell interactions and cytokine production14–16. For 
example, CD8+ T cells secreting interferon γ (IFNγ ) promote macrophage infiltration into the adipose tissue, 
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leading to inflammation and subsequent insulin resistance15. The proportion of regulatory T (Treg) cells is often 
decreased in adipose tissue of obese individuals which also facilitates tissue inflammation14,17. Unlike the other 
VSC immune cell populations, adipose tissue B cells (ATBs), which represent over 20% of VSCs in obese individ-
uals18,19, are poorly understood.
ATBs dramatically increase in both absolute number and relative proportion of visceral stromal cells during 
the development of obesity18,19. In mouse models of obesity, the accumulation of B cells in visceral adipose tissues 
peaks 3–4 weeks after initiating high-fat diet (HFD)19. ATBs serve as crucial antigen presenting cells within adi-
pose tissue. Mice with defects in B cell formation display significantly lower obesity-induced insulin resistance 
accompanied with reduced antibody production and perturbed cell-cell interactions18,19. The regulatory mecha-
nisms modulating ATB response in the face of obesity are yet to be uncovered.
Our previous studies identified microRNAs as crucial regulators controlling ATM polarization and B cell 
formation13,20,21. miR-150 has been identified as a crucial regulator of B cell formation and function20–22. Ectopic 
expression of miR-150 in hematopoietic stem cells resulted in impaired B cell production by blocking transition 
from the pro-B to pre-B cell stage without detectable effects on other hematopoietic lineages21. In contrast, miR-
150 deficiency in mice didn’t significantly alter formation of blood cell lineages derived from hematopoietic stem 
cells20. Furthermore, miR-150KO mice exhibited increased antibody production in the face of antigen challenge20. 
Several target genes of miR-150, including Myb (v-myb avian myeloblastosis viral oncogene homolog), Cbl (cbl 
proto-oncogene, E3 ubiquitin protein ligase), Egr2 (early growth response 2), Gab1 (GRB2-associated binding 
protein 1), and Foxp1 (forkhead box P120,22,23, are important for B cell formation and function through their effect 
on various pathways. However, none of these pathways have been explored in the context of ATBs and obesity.
In this study, we show for the first time that miR-150 regulates obesity-induced metainflammation and insulin 
resistance by controlling ATB function. Using various mouse models, including miR-150KO mice and wild type 
mice with adoptive transplantation of B cells or antibodies isolated from obese mice, we demonstrate that miR-
150 controls activation of ATBs by enhancing the B cell receptor (BCR)-mediated pathways and antigen pres-
entation which is partially mediated by the Myb, Etf1 (eukaryotic translation termination factor 1) and Elk1 (ETS 
domain-containing protein) genes. Our results suggest miR-150KO ATBs primarily act through cell-cell interac-
tions, as opposed to pathogenic antibody production, to promote T cell and macrophage activation, resulting in 
metainflammation and systemic insulin resistance. Our study provides novel insight into microRNA’s regulation 
of ATBs in an obese context which might identify potential drug targets to mitigate obesity-induced metabolic 
syndromes.
Results
miR-150 deficiency exacerbates obesity-induced metainflammation and systemic insulin 
resistance. We first investigated the cell composition in VSCs of lean and diet-induced obese mice. 
As expected, adipose tissue immune cells were significantly increased in both proportion and absolute 
cell numbers in the visceral adipose tissue (Fig. 1). ATMs increased from 15% to 35% of VAT immune cells 
(0.83 ± 0.15 × 104 cells/g in lean VAT to 2.34 ± 0.30 × 104 cells/g in obese VAT) (Fig. 1A), and CD3+ ATTs 
increased from 6% (0.29 ± 0.08 × 104 cells/g of lean VAT) to 15% (1.6 ± 0.36 × 104 cells/g of obese VAT) 
(Fig. 1A,B). Notably, ATB numbers also significantly increased from 8% (0.33 ± 0.09 × 104 cells/g of VAT) in 
lean to 20% of immune cells (1.22 ± 0.30 × 104 cells/g of VAT) in obese mice (Fig. 1C). Surprisingly, mice with 
miR-150 depletion (miR-150KO) did not exhibit significantly different proportions of ATMs, ATTs, or ATBs 
as determined by flow cytometry and immunostaining analysis (Fig. 1A–D). Obese WT and miR-150KO mice 
exhibited similar circulating or splenic immune cell populations compared to each other and their lean coun-
terparts (Supplementary Figures S1 and S2), including total B cells (CD19+), T cells (CD3+), neutrophils 
(CD11b + Gr1+) and monocytes (CD11b + Gr1-F4/80). Therefore, it is unlikely that elevated populations of 
immune cells in VAT are simply a result of enhanced hematopoiesis.
Despite similar food intake and body weight gain over a 12-week feeding period (Supplementary Figure S3A 
and B), as well as comparable adiposity (Supplementary Figure S3C), HFD-miR-150KO mice exhibited severely 
exacerbated obesity-induced metainflammation and insulin resistance (Figs 2 and 3). At a systemic level, concen-
trations of inflammatory cytokines and chemokines in plasma, including tumor necrosis factor α (TNFα ), inter-
leukin (IL) 1β , IL6 and chemokine (C-C motif) ligand 2 (CCL2), were significantly increased (Fig. 2A) in obese 
wild type mice compared to age-matched lean mice fed a low-fat diet (LFD); whereas concentrations of IL10 in 
plasma (Fig. 2B) were significantly lower in obese mice. The overall proinflammatory pattern of cytokines in 
plasma was even greater in miR-150KO mice fed a HFD (Fig. 2A,B). For example, expression of TNFα , IL1β , IL6 
and CCL2 was significantly higher in the visceral fat pads from HFD-miR-150KO mice than from HFD-WT mice 
(Fig. 2C,D). The elevated inflammatory milieu in HFD-miR-150KO mice was further confirmed by enhanced 
activation of JNK pathway in visceral white fat (Fig. 2E).
MiR-150 null mice also developed severe obesity-induced hyperglycemia and hyperinsulinemia. Under both 
fed and fasted conditions, HFD-miR150KO mice exhibited significantly higher plasma levels of glucose (Fig. 3A) 
and insulin (Fig. 3B) than HFD-WT mice; whereas both glucose and insulin levels were similar in mutant and 
wild type mice on chow diet (Fig. 3A,B). These results suggest that the impact of miR-150 deletion is unmasked 
by HFD-induced obesity. Indeed, when challenged with a single dose of glucose (2 g/kg) or insulin (1 U/kg), 
miR-150KO mice on HFD, but not on LFD, exhibited severe glucose intolerance (Fig. 3C) and insulin resistance 
(Fig. 3D) compared to wild type mice. Furthermore, analysis of Akt activation in VAT and liver after portal vein 
insulin injection indicated that miR-150 deficiency significantly impaired the insulin signaling pathway in mice 
under obese stress. Although Akt activation in the skeletal muscle did not reach statistical significance, it did dis-
play a consistent trend towards decreased activation in miR-150KO animals (Fig. 3E, Supplementary Figure S4). 
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Taken together, these results suggest that miR-150 is a crucial regulator of metabolic function in adipose tissue of 
mice with diet-induced obesity.
miR-150 deficiency directly enhances adipose tissue B cell function. In addition to the dysregu-
lated metabolic phenotype observed in miR-150KO mice, our analysis of individual immune compartments in 
VAT revealed that the enhanced ATB activation profile in obesity was further exacerbated by miR-150 deficiency 
(Supplementary Figure S5). Furthermore, obese miR150KO ATMs displayed a more proinflammatory phenotype 
compared to WT obese ATMs as demonstrated by increased proportions of proinflammatory CD206-CD11c+ 
M1 macrophages and significantly enhanced proinflammatory gene expression (Supplementary Figure S6). We 
did not observe similar differences in CD4+ and CD8+ ATT activation profiles (Supplementary Figure S5).
Next, we determined whether loss of miR-150 alters B cell, T cell or macrophage activation directly or indi-
rectly using two sets of experiments: (a) purified cell populations subjected to activation; or (b) co-culture 
analysis to examine cell-cell interaction mediated activation. We found that loss of miR-150KO did not sig-
nificantly change the activation profiles of macrophages with respect to polarized or acute phase stimulation 
(Supplementary Figures S7 and S8). Similarly, isolated miR-150KO CD4+ or CD8+ T cells responded to stimuli 
identically to wild type T cells with respect to surface marker induction and cytokine production (Supplementary 
Figures S7 and S9). Interestingly, isolated miR-150KO B220+ B cells displayed significantly enhanced activation 
profiles compared to wild type B cells when subjected to either LPS (T cell-independent, TI) or IL4/anti-CD40 
(T cell-dependent, TD) (Fig. 4A), although PMA/ionomycin short-term treatment did not alter the activation 
profiles (Supplementary Figure S7). Compared to wild type B cells, we observed a dramatic increase in the pro-
portion of miR-150KO B cells that displayed major histocompatibility complex II (MHCII) on the cell membrane 
at 72 hours post stimulation with TI stimuli (Fig. 4A). miR-150KO B cells also exhibited higher membrane levels 
of MHCII complex than wild type B cells exposed to TD stimuli (Fig. 4B). These findings are consistent with the 
elevated immunoglobulin levels in plasma from HFD-miR-150KO mice compared to wild type mice (Fig. 4C). 
Higher levels of IgA and IgG subtypes IgG1 and IgG2b, and enhanced interferon γ (IFNγ ) expression post stim-
ulation, were observed in plasma of HFD-miR150KO mice (Fig. 4C,D,E). Given the essential role of BCR signa-
ling in initiating B cell responses24,25, we further evaluated gene expression of BCR-mediated signaling pathway 
components. Several important components of this pathway were significantly increased, including Syk (spleen 
tyrosine kinase), Lyn(v-yes-1 yamaguchi sarcoma viral related oncogene homolog) and Src (v-src avian sarcoma 
(Schmidt-Ruppin A-2) viral oncogene homolog), suggesting that enhanced B cell responses due to miR-150 defi-
ciency are likely BCR-dependent (Fig. 4F). In summary, these results suggest that miR-150 deficiency does not 
directly affect macrophage polarization or T cell activation, but can enhance B cell activity in response to stimuli.
Figure 1. The recruitment of immune cells is dramatically increased during obesity. The population of 
adipose tissue macrophages (A; ATM), adipose tissue B cells (B; ATB), and adipose tissue T cells (C; ATT) in 
visceral stromal cells (VSC) of visceral adipose tissues (VAT) of wild type (WT) or miR-150KO mice with or 
without high-fat diet (HFD). n = 7–10 (D) Immune cell components in VAT of HFD-fed WT and miR-150KO 
mice detected by immunostaining analysis. Scale bar, 100 μ m. Data are presented as mean ± SEM.
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miR-150KO ATBs are critical contributors to obesity associated glucose intolerance. We 
observed dramatically reduced expression of miR-150 in VAT B-cells isolated from obese mice (Fig. 5A). To 
understand if miR-150 null B cells are major contributors to obesity-associated chronic inflammation and sys-
temic inflammation, we utilized an adoptive transplantation assay. Splenic B cells isolated from obese mice were 
validated for purity and viability (Supplementary Figure S12) and injected into mice lacking endogenous B cells 
due to mutations in the expression of IgM (Bnull; Supplementary Figure S13) and fed a HFD for 12 weeks26. Body 
weight gain and adiposity were monitored post transplantation and significance differences were not observed 
between mice that received 1 × 107 B cells from either HFD-miR-150KO (BmiR-150KO) or HFD-WT (BWT) mice 
(Supplementary Figure S14). Engraftment of BmiR-150KO or BWT cells in the adipose tissue was confirmed using 
flow cytometric analysis (Fig. 5B). As expected, HFD-Bnull mice that received WT or miR 150KO B cells displayed 
a comparable cell composition of ATBs (Fig. 5A), ATMs (Fig. 5C), and ATTs (Fig. 5D) in VSCs. Two weeks after 
B cell transplantation, recipient mice were subjected to a glucose tolerant test. Consistent with previous obser-
vations19, Bnull mice fed a LFD had glucose responses that were indistinguishable from wild type mice; however, 
after HFD feeding, Bnull mice exhibited less glucose intolerance compared to HFD-WT mice (Supplementary 
Figure S15). Following adoptive transplantation, HFD-Bnull mice that received WT B cells displayed higher glu-
cose intolerance compared to non-B cell transplanted mice (Fig. 5E). Moreover, transplantation of BmiR-150KO cells 
into HFD-Bnull mice exacerbated the glucose intolerance observed in HFD-Bnull-BWT mice (Fig. 5E). Furthermore, 
transplantation of obese BmiR-150KO cells significantly increased the elevated fasting plasma insulin and glucose 
seen in HFD-Bnull-BWT mice (Supplementary Figure S15). Transplantation of WT B cells into obese VAT also 
increased VAT inflammatory gene expression, which was further elevated in BmiR-150KO transplanted animals 
(Supplementary Figure S16). These results suggest that miR-150 deficiency in B cells is sufficient to exacerbate 
glucose intolerance in obese mice.
miR-150 regulates B cell-dependent interactions with macrophages and T cells ultimately alter-
ing adipose tissue function. Given that B cells are major antigen presenting cells in the adipose tissue niche 
and the primary source of immunoglobulins27–30, we further investigated if miR-150 regulated B cells by altering 
their cell-cell interactions or production of immunoglobulins in the adipose tissue niche. HFD-miR-150KO mice 
exhibited higher amounts of immunoglobulin in plasma than HFD-WT mice (Fig. 4C); therefore we purified 
immunoglobulins using the NAbTM Protein L Spin kit (Supplementary Figure S17). Purified immunoglobulins 
Figure 2. miR-150 regulates obesity-induced inflammation.  (A,B) Concentrations of cytokines in plasma of 
wild type or miR-150KO mice with or without HFD. n = 7–10. (C) The expression of inflammatory cytokines 
tumor necrosis factor-α (TNFα ), interleukin (IL) 1β , IL6, and chemokine (C-C motif) ligand 2 (CCL2) in 
VAT of HFD-fed mice. n = 3. (D) The expression of IL10 in VAT of HFD-fed mice. n = 3. (E) Activation of 
c-Jun N-terminal kinases (JNK) signaling pathway in VAT of mice on a HFD. MFI, medium fluorescence 
intensity. n = 7–8. (F) Activation of nuclear factor-κ B (NFκ B) pathway in VAT of HFD-fed mice. n = 4. Data are 
presented as mean ± SEM. *P < 0.05, **P < 0.001, ***P < 0.0001, Student’s t test.
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were injected into HFD-Bnull mice, which have no endogenous immunoglobulin production. Body weight gain 
was monitored followed by a glucose tolerance test at 7 days post injection of antibody. Surprisingly, glucose intol-
erance was similar in mice receiving purified immunoglobulin from miR-150KO or WT mice (Supplementary 
Figure S18). Although our results do not totally rule out the importance of total immunoglobulins in controlling 
obesity-induced glucose intolerance, it is likely that the effects of miR-150 on obesity-induced insulin resistance 
are not related to production of pathogenic antibodies.
Next, we investigated if miR-150 modulates B-cell interactions with other cell types in the adipose tissue niche. 
First, we co-cultured purified mature adipocytes from HFD-WT mice with activated WT or miR-150KO B cells. 
Interestingly, no significant difference was observed in the adipocytes with respect to production of proinflam-
matory cytokines (Supplementary Figure S19). Although loss of miR-150 did not significantly affect the responses 
of purified T cells or macrophages to stimuli, it is possible that enhanced activation of ATBs enhances their 
activities in VSCs from obese individuals through cell-cell interactions. Therefore, we examined activation of T 
cells and macrophage in the presence of B cells with or without miR-150 deletion. Wild type CD4+ and CD8+ 
T cells displayed a higher response to CD3-CD28 activation when co-cultured with activated miR-150KO B cells 
compared to wild type B cells, resulting in higher levels of activation-related surface markers and increased pro-
duction of IFNγ and IL2 (Fig. 6A–D). Although miR-150 depletion in macrophages did not alter their activation 
(Supplementary Figure S4), proinflammatory M1 macrophages co-cultured with miR-150KO B cells displayed 
a significantly enhanced proinflammatory activation profile, including activation-related surface markers and 
production of cytokines (Fig. 6E,F). M2 cells showed a similar activation status when co-cultured with either 
WT or miR-150KO B cells (Fig. 6G,H). Taken together, these results suggest that miR-150 potentially modulates 
obesity induced adipose tissue inflammation through controlling B cell function interactions with macrophages 
and T cells.
Several genes targeted by miR-150 mediate its regulation of B cell functions. MicroRNAs 
exert their biological functions by either blocking translation and/or inducing degradation of target mRNAs by 
base-pairing to recognition sites31,32. Myb is reported to be an important target gene of miR-150 during B cell 
formation and activation20,33–37. Utilizing prediction algorithms, TargetScan Mouse 6.238 and PicTar39, we iden-
tified several additional genes bearing miR-150 target sites. Using a luciferase reporter assay, we confirmed that 
Elk1 and Etf1 are bona fide miR-150 target genes as evidenced by suppression in their luciferase activities in the 
presence of miR-150 (Fig. 7A). In contrast, mutation of the miR-150 binding site in the 3′ untranslated regions 
(UTR) of Elk1 and Etf1 prevented inhibition of luciferase activity by miR-150 (Fig. 7A). Expression of miR-150 
target genes Elk1, Etf1, and Myb was also enhanced in miR-150KO B cells during in vitro activation (Fig. 7B). 
To further evaluate the effects of target genes on B cell functions, we knocked down expression of these genes 
in isolated B cells with short hairpin RNA (shRNA) constructs. The knockdown efficacy was evaluated in trans-
fected cells by quantitative PCR analysis (Supplementary Figure S20). Intriguingly, knockdown of Myb, Etf1, or 
Elk1 significantly decreased activation of B cells with respect to activation of BCR signaling pathways and MHC 
Figure 3. miR-150 ablation exacerbates obesity-induced systemic insulin resistance. (A,B) Concentrations 
of glucose and insulin in plasma of miR-150KO mice or wild type mice fed a HFD or a low-fat diet (LFD), or 
fasted for 16 hours. n = 6–10. (C,D) Glucose tolerance test and insulin tolerance test after 12 weeks of feeding. 
n = 6–10. (E) Activation of Akt signaling pathway in VAT of mice on a HFD 5 minutes following an acute 
insulin injection. n = 4. Data are presented as mean ± SEM. *P < 0.05, Student’s t test.
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II membrane expression, as compared to miR-150KO B cells infected with a control vector harboring scrambled 
target sites (Fig. 7C,D). These results demonstrated that Myb, Elk1 and Etf1 are bona fide targets of miR-150, and 
play critical roles in mediating miR-150’s effects on B cell functions.
Discussion
Chronic adipose tissue inflammation is a major pathogenic phenotype associated with obesity1,2,4. Dramatic 
increases in immune cell populations and their enhanced inflammatory capabilities alter adipose tissue functions 
to exacerbate pre-diabetic conditions, including systemic insulin resistance and inflammation5,15,40,41. Within 
the adipose tissue, B cells contribute more than 20% of the stromal cell population18,19. However, their overall 
impact on physiological alterations, both metabolic and inflammatory, and mechanisms underlying their actions 
in adipose tissues of obese individuals are poorly defined. In this study, we found that miR-150, a hematopoietic 
enriched microRNA exerting profound regulatory effects on B cell formation and function, is a novel molecule 
regulating obesity-associated adipose tissue inflammation and insulin resistance.
Previous studies identified several hematopoietic enriched microRNAs including miR-150, which is a crit-
ical regulator of B cell formation20,21. Ectopic expression of miR-150 in all tissues or in hematopoietic stem 
cells, significantly and specifically impairs B lineage development by blocking the transition from pro-B to 
pre-B stages. Interestingly, deletion of miR-150 resulted in undetectable changes in hematopoietic lineages and 
non-hematopoietic tissues, but increased B cell activation in response to stimuli. Indeed, we observed exacerbated 
pre-diabetic conditions, including elevated levels of insulin and cytokines, in miR-150KO mice compared to 
wild-type controls fed a HFD. Furthermore, we now confirm that deletion of miR-150 in B cells significantly alters 
B cell activation in response to both T cell-dependent and T cell-independent stimuli with respect to increasing 
activation of BCR signaling pathways and immunoglobulin production (Fig. 4). More importantly, miR-150 sig-
nificantly affects antigen presentation on the B cell membrane, as evidenced by a higher abundance of MHC II on 
miR-150 null B cells in response to stimuli (Fig. 4).
Our adoptive transplantation model using Bnull mice demonstrated that the transfer of B cells from 
HFD-miR150 or HFD-WT mice partially recapitulated the insulin resistance characteristic of miR-150 mutant 
mice (Fig. 5D). Winer et al. suggested that immunoglobulin production by B cells could contribute to insulin 
resistance19; however, we failed to observe such a contribution in response to purified immunoglobulins from 
HFD-miR-150KO or HFD-WT mice. We observed that B cells lacking miR-150 displayed a slight increase in 
immunoglobulin production, which could partially contribute to higher circulating levels of IgG and IgA in 
plasma of mice fed a HFD. However, the specific contribution of immunoglobulins produced by B cells, especially 
Figure 4. miR-150 is an important regulator of adipose tissue B cell function. (A,B) The production of MHC 
II by splenic B cells after stimulation with lipopolysaccharide (LPS, 10 μ g/mL) or IL4 (10 ng/mL)/anti-CD40 
(10 μ g/mL). n = 9. (C) The concentration of immunoglobulins (Ig) in plasma of mice on a HFD. n = 7–10. 
(D,E) The gene expression of interferon (IFN) γ by B cells after 72 hours LPS or IL4/anti-CD40 stimulation. 
n = 4. (F) The gene expression of B cell receptor (BCR) signaling pathway components in WT or miR-150KO 
B cells. n = 3. Splenic B cells were derived from 6–8 week old WT or miR-150KO chow diet fed mice. Data are 
presented as mean ± SEM. *P < 0.05, **P < 0.001, Student’s t test.
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adipose tissue B cells, to the development of insulin resistance needs to be further investigated. Taken together, 
our results suggest that B cells in adipose tissue are primary contributors to adipose tissue inflammation and 
systemic insulin resistance in obese miR-150KO mice.
Although loss of miR-150 did not significantly alter activation states of macrophages and T cells under the 
obese stress(Supplementary Figures S4 and S5)21, the overall proinflammatory profile was enhanced (Fig. 2). We 
confirmed that miR-150KO B cells can enhance both T cell and macrophage activation profiles (Fig. 6) which can 
impair insulin tolerance in adipose tissue transplanted with miR-150KO B cells (Fig. 5D). In addition, enhanced 
T cell and macrophage infiltration into adipose tissue in the adoptive transplantation model suggests that ATBs 
release cytokines promoting the recruitment of immune cells in obesity. Together with increased T cells and mac-
rophages, adipose tissue B cells exacerbate obesity-induced chronic inflammatory features in the adipose tissue 
and subsequent systemic insulin resistance (Fig. 8).
Our understanding of the B cell contribution to adipose tissue function, especially under the stress of obe-
sity, is in its infancy. In this study, we demonstrate that miR-150, a B cell enriched regulatory microRNA, plays 
a role in modulating the pathogenesis of obesity associated adipose tissue inflammation and insulin resistance, 
which are major contributors to metabolic syndrome and development of type 2 diabetes. The ability of miR-
150 to simultaneously target multiple genes allows it to exert a potent impact by altering signaling networks 
governing adipose tissue B cell function (Fig. 8). These miR-150 target genes, Myb, Elk1, and Etf1, are known 
to be important in regulating B cell differentiation and function. For example, the transcription factor MYB is 
required for the expression of IL7 receptor and EBF1 that are essential for the intrinsic survival of pro-B cells34. 
ELK1 is a downstream component of ERK kinases-mediated pathways that are critical for the pre-BCR-regulated 
early B cell expansion42. ETF1 is critical to control the translation of messenger RNAs into protein by its proper-
ties as a polypeptide chain release factor43. Surprisingly, our results indicated that knockdown of these miR-150 
targets reduced expression of upstream BCR signaling pathway components (i.e. src and lyn), suggesting the 
potential involvement of miR-150 in modulating a feedback circuit in B cell activation. Further investigation 
regarding the mechanisms of miR-150 and B cell action will greatly facilitate development of therapeutics treating 
obesity-associated complications by targeting microRNAs and modulating B cells.
Methods
Animal Experiments. The generation of miR-150-deficient (miR-150KO) and Bnull B6 mice has been pre-
viously described21,26. Wild-type (WT) C57BL/6J mice were used as controls. All mice were maintained on a 
12/12-hour light-dark cycle. Male mice 5 to 6 weeks of age were fed ad libitum. Mice were fed a high-fat diet (60% 
Figure 5. miR-150 deficiency-dependent insulin resistance is mediated by adipose tissue B cells. (A) miR-
150 expression in B cells of lean and obese mice. n = 4. (B–D) The infiltration of B cells (CD19+ ), macrophages 
(F4/80 + CD11b+ ), and CD3+ T cells in VSC of HFD-Bnull mice after 2 weeks injection of B cells. n = 5–8.  
(E) Glucose tolerance test of HFD-fed Bnull mice after 2 weeks injection of B cells. n = 7–8. HFD-Bnull-BmiR-150KO, 
HFD-fed Bnull mice injected with miR-150KO B cells; HFD- Bnull-BWT, HFD-fed Bnull mice injected with WT B 
cells. Data are presented as mean ± SEM. *P < 0.05, ***P < 0.0001, Student’s t test.
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fat calories, 20% protein calories, and 20% carbohydrate calories) or a low-fat diet (10% fat calories, 20% protein 
calories, and 70% carbohydrate calories) for 12 weeks. After the feeding regimen, mice were subjected to pheno-
type characterization and metabolic assays, including measurement of metabolic parameters in plasma, insulin 
and glucose tolerance tests.
Acute Insulin Challenge. We performed portal vein insulin injection to assay the sensitivity of the insulin 
signaling pathway (Humulin R, Eli Lilly). Following the 12-week feeding period, HFD-fed mice were fasted for 
16 hours. Subsequently, mice were anesthetized with inhaled isoflurane, their abdominal cavity opened and portal 
vein exposed. An insulin bolus (2 U/Kg body weight in 100 ul normal saline) was injected into the portal vein. 
Within 5 minutes of the injection, liver, skeletal muscle, and VAT were excised and snap frozen in liquid nitrogen. 
Samples were stored in − 80 °C until further processing.
Purification and transfer of B cells. After 12-week on a HFD, spleens were collected from HFD-fed 
WT and miR-150KO mice and mechanically dissociated. After lysing red blood cells, single splenic B220+ B 
cells were purified by using anti-mouse CD45R/B220 conjugated to magnetic particles (Cat. No. 551513, BD 
Biosciences). B cell purity and B cell subtypes were determined by flow cytometry using an antibody against 
B220 (Supplementary Figure S12). A total of 1 × 107 B220+ B cells in 150 μ L of PBS were transferred into each 
HFD-fed Bnull mouse via intraperitoneal (i.p.) injection. HFD Bnull mice without B cell transfer served as controls. 
Glucose tolerance was determined 2 weeks after the B cell injection.
Isolation and transfer of immunoglobulin. Immunoglobulin proteins were isolated from plasma 
of HFD-WT or miR-150KO mice using NAbTM Protein L Spin kit (Cat. No. 89981, Life Technologies). 
Immunoglobulin proteins were validated by gel electrophoresis (Supplementary Figure S17). A total of 150 μ g of 
purified proteins in 150 μ L of PBS were transferred into each HFD-fed Bnull mouse via intraperitoneal injection 
on Day 0 and Day 3. HFD-fed Bnull mice without immunoglobulin protein transfer served as controls. A glucose 
tolerance test was performed 1 week after injection of immunoglobulin.
Isolation of stromal cells from visceral adipose tissues (VATs). Visceral adipose tissues was mechan-
ically chopped and then digested with collagenase II (Cat. No. 17101, Life Technologies) for 30 min at 37 oC. After 
lysing red blood cells and passing cells through a 200 μ m cell strainer, visceral fat stromal cells were collected 
following centrifugation at 1000 x g for 5 mins.
Figure 6. miR-150 may modulate obesity-associated insulin resistance and tissue inflammation by 
regulating B cell interactions with other immune cells. (A–D) The activation of CD4+ T cells (T4) or CD8+ 
T cells (T8) after co-culture with activated WT or miR-150KO B cells. n = 6. (E–H) The expression level of 
BMDM activation-related surface markers and key genes after 48 hours co-cultured with activated WT or miR-
150KO B cells. Splenic CD4+ or CD8+ T cells and B cells were used for co-culture experiments. All T cells, 
B cells, and BMDMs were derived from 4–6 week old miR-150KO or WT chow diet fed mice. n = 6. Data are 
presented as mean ± SEM. *P < 0.05, **P < 0.001, Student’s t test.
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Immunoglobulin concentration measurement. Concentrations of immunoglobulin including IgA, 
IgE, IgG1, IgG2a, IgG2b, IgG2c, and total IgG in plasma or B cell culture supernatant were measured using ELISA 
kits (Cat. No. 88-550450-22, eBioscience) according to the manufacturer’s instructions.
Macrophage and T cell isolation. Bone marrow-derived macrophages were prepared as previously 
described44. Macrophage maturation was examined by flow cytometry with antibodies against F4/80 and CD11b 
(Supplementary Figure S21A). CD4+ or CD8+ T cells were isolated by using anti-mouse CD4 (Cat. No. 551539) 
or CD8 (Cat. No. 557766) conjugated to magnetic particles (BD Biosciences), respectively. T cell purity was 
evaluated by flow cytometry with antibodies against CD4 (Cat. No. 53-0041-82, eBioscience) or CD8 (Cat. No. 
17-0081-82, eBioscience) (Supplementary Figure S21B and C).
Splenocyte Activation Assay. Isolated splenic WT or miR-150KO B cells were activated for 72-hours 
with 10 μ g/mL LPS, 10 ng/mL IL4 or 10 μ g/mL anti-CD40 (Cat. No. 16-0401-85, eBioscience). Splenic CD4+ 
and CD8+ T-cells were activated with anti-CD3 (Cat. No. 14-0032-85, eBioscience) and anti-CD28 (Cat. No. 
14-02281-86, eBioscience). Alternatively, CD4+ and CD8+ T cells, B-cells, and splenic macrophages were acti-
vated with a 5 hr PMA/ionomycin cocktail (Cat. No. E13495-124, eBioscience) in the presence of a protein trans-
port inhibitor (Cat. No. 13496-122, eBioscience) per the manufacturer’s instructions.
Co-culture assay. Following 72-hour activation with 10 μ g/mL LPS, 10 ng/mL IL4 or 10 μ g/mL anti-CD40, 
WT or miR-150KO B cells were mixed with WT CD4+ or CD8+ T cells at a ratio of 1:10 in the presence of anti 
CD3 and CD28. Activated WT B cells or miR-150KO B cells were also co-cultured with WT M1 or M2 BMDMs at 
a ratio of 1:10 using a trans-well plate. The activation of BMDMs or T cells was examined by flow cytometry with 
antibodies against CD69, CD80, CD86, IL2 or IFNγ after 48 h co-culture.
Macrophage polarization analysis. A macrophage polarization assay was carried out following the pro-
tocol described previously44. To induce proinflammatory M1 macrophages, BMDMs were stimulated with LPS 
(100 ng/mL). IL4 (20 ng/mL) was used to induce anti-inflammatory M2 macrophages. After 48 h of stimulation, 
Figure 7. miR-150 controls B cell functions through multiple target genes. (A) Reporter constructs 
containing a 3′ untranslated region (UTR) with WT or mutated miR-150 binding sites of target genes (mut). 
n = 3. (B) After 72-hour activation, the expression of miR-150 target genes in splenic WT or miR-150KO B cells. 
n = 3. (C) The activation of BCR signaling pathways in miR-150KO B cells with knockdown of miR-150 target 
genes in response to LPS stimulation. n = 3. (D) MHC II production by miR-150KO B cells after knockdown 
of miR-150 target genes in response to LPS stimulation. Splenic B cells were derived from 6–8 week old miR-
150KO chow-diet fed mice. n = 6. Data are presented as mean ± SEM. *P < 0.05, **P < 0.001, Student’s t test.
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BMDMs were examined by flow cytometry with antibodies against CD69 (Cat. No. 45-0691-82, eBioscience), 
CD80 (Cat. No. 12-0801-85, eBioscience), and CD86 (Cat. No. 17-0862-82, eBioscience).
Flow cytometry analysis. Unless otherwise specified, we purchased antibodies from eBioscience. Visceral 
stromal cells and splenic cells were stained with fluorescence-tagged antibodies to detect cell lineages. B cell 
subtypes were detected with antibodies against CD19 (Cat. No. 17-0193-82), CD5 (Cat. No. 11-0051-82) and 
CD43 (Cat. No. 12-0431-82); T cells were detected with antibodies against CD3 (Cat. No. 12-0031-82), CD4 or 
CD8; myeloid cells were detected with antibodies against F4/80 (Cat. No. 53-4801-82), CD11b (Cat. No. 17-0112-
83) and Gr-1 (Cat. No. 45-5931-80); macrophage subtypes were detected with antibodies against F4/80, CD11b, 
CD206 (Cat. No. 141706, Biolegend), CD11c (Cat. No. 12-0114-83). Macrophage activation was measured with 
antibodies against CD80, CD69, CD86, TNFα (Cat No. 12-7321-41), and IL1β (Cat No.11-7114-80). T cell acti-
vation was measured using antibodies against CD80, CD86, CD69, IFNγ (Cat. No. 25-7311-82), and IL2 (Cat. 
No. 12-7021-82). B cell activation was measured using antibodies against CD80, CD86, CD69, and MHC II (Cat. 
No. 56-5321-82). Data were analyzed using Flowjo software or Accuri C6 software (BD Biosciences) or Kaluza 
software (Beckman Coulter).
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis. Total RNA 
was extracted from adipose tissue B cells or BMDMs using the Trizol extraction protocol according to the manu-
facturer’s instructions. Gene expression analysis was performed using a iScript One-Step RT-PCR kit with SYBR 
Green (Bio-Rad) on Bio-Rad CFX384 (Bio-Rad). The data presented correspond to the mean of 2−ΔΔCt from at 
least three independent experiments after being normalized to β -actin. A list of primers and their sequences is 
presented in Supplementary Figure S22.
Bio-Plex protein expression assay. The concentrations of IL1β , TNFα , IL6, IL10, and chemokine (C-C 
motif) ligand 2 (CCL2) in plasma were determined using a Bio-PlexTM Cytokine Assay (Cat No. M60-009RDPD, 
Bio-Rad). Concentrations of insulin in plasma were determined using the Bio-Plex Pro Mouse Diabetes Insulin 
set (Cat. No. 171-G7006M, Bio-Rad). The levels of total and phosphorylated JNK in mature adipocytes were 
determined using the Bio-Plex Cell Signaling Magnetic Assays (Cat. No. 171-V50003M, Bio-Rad). β -actin (Cat. 
No. 171-V60020M, Bio-Rad) was used as the internal control. These Bio-Plex assays were performed using the 
Bio-Plex MAGPIXTM multiplex reader (Bio-Rad). Results were analyzed using Bio-Plex Data ProTM software 
(Bio-Rad).
Immunohistochemistry. Tissues collected from HFD-fed mice were fixed and stained with antibod-
ies against F4/80 (Cat. No. 14-4801-82, eBioscience), B220 (Cat. No. 14-0452-82, eBioscience), CD3 (Cat. No. 
14-0032-82, eBioscience) to detect macrophages, B cells, and T cells. Immunoglobulin protein was used as the 
Figure 8. Schematic model of miR-150-mediated molecular network in B cells. 673 miR-150 directly 
suppresses the expression of target genes, Elk1, Myb, Etf1, which are 674 critical mediators of activation of 
the B cell receptor (BCR) signaling cascade. This miR-675 150-mediated B cell function is also critical for the 
activation of T cells and 676 macrophages residing in adipose tissues, eventually exerting profound impacts on 
the 677 function of adipocytes. Elk1, ETS domain-containing protein. Myb, myeloblastosis 678 oncogene. Etf1, 
eukaryotic translation termination factor 1. SYK, spleen tyrosine kinase. 679 LYN, tyrosine-protein kinase. 
ERK, extracellular regulated MAP kinase. PI3K, 680 phosphoinositide 3-kinase. PKC, protein kinase C. BLNK, 
B-cell linker. BTK, Bruton’s 681 tyrosine kinase. PLCγ 2, phospholipase C, gamma 2. VAV, guanine nucleotide 
682 exchange factor. Figure contributed by W. Ying.
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negative control. Images were captured using a Zeiss Stallion Dual Detector Imaging System with Intelligent 
Imaging Innovations Software (Carl Zeiss).
Western blotting. After homogenization using the BeadBugTM microtube homogenizer (Benchmark 
Scientific), total protein was extracted from VATs using lysis buffer (Cell Signaling Technology). Protein concen-
trations were determined using the Bradford assay. Proteins were separated on PROTEAN® TGX Stain-FreeTM 
Precast Gel (Bio-Rad) and transferred onto a polyvinylidene fluoride (PVDF) membrane followed by detection 
using antibodies directed against total Akt (Cat. No. 9272, Cell Signaling Technology) and phosphorylated Akt 
(Cat. No. 9271, Cell Signaling Technology).
Luciferase reporter assay. The luciferase reporter assay was carried out following the protocol described 
previously10). Briefly, the full 3′-untranslated region (3′-UTR) sequence of the predicted target gene or at least 
250-bp flanking the predicted miR-150 binding site was cloned into the psiCheck2 Vector (Promega) down-
stream of the Renilla luciferase-coding region. The reporter constructs were cotransfected with miR-150 mimic 
oligonucleotides or negative control oligonucleotides into HEK293 cells. After 48 h co-transfection, the activities 
of Renilla luciferase were measured with Dual-Glo luciferase reporter system (Promega) and normalized to the 
internal control firefly luciferase activity. Repressive effects of miR-150 on target genes were plotted as the per-
centage repression in three biological repeats that each contained three technical repeats.
Lentiviral shRNA assay. The pLKO.1-CMV-TurboGFPTM vector (Sigma-Aldrich) with inserted shRNA 
(targeting Myb, Elk1 or Etf1) was co-transfected with compatible packaging plasmids into HEK293T cells. The 
lentiviral supernatants were collected after 72 h transfection and used to infect purified splenic miR-150 null 
B220+ B cells. Control vector with scramble target sites was used as the control.
Data and statistical analyses. Results are expressed as means ± SEM. Each data point derived from 
qRT-PCR assays represents an average of two technical replicates, and data were averaged over independently 
replicated experiments (n = 3–4 independently collected samples) and analyzed using the Student’s t test. The 
overall group-effect was analyzed for significance using two-way ANOVA and Bonferroni post-test for each factor 
at each individual time. Data analyses were performed using Graphpad Prism version 6.0 software. A value of 
P < 0.05 was considered statistically significant.
Study approval. All study protocols were reviewed and approved by the Institutional Animal Care and Use 
Committee of Texas A&M University. Methods were carried out in accordance with relevant and approved guide-
lines and regulations.
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